Jennifer Altreuter

发表

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.

N. Lennon, A. Giobbie-Hurder, R. Mak, 2022, The Lancet. Oncology.

The Ubiquitin-Specific Peptidase USP15 Regulates Human Papillomavirus Type 16 E6 Protein Stability

P. Howley, E. White, Jennifer Altreuter, 2009, Journal of Virology.

397 Deep myeloid cell profiling provides new insights into modulators of CAR T cell expansion in patients with solid tumor malignancies

H. Maecker, F. Michor, B. Sahaf, 2022, Regular and Young Investigator Award Abstracts.

Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.

Shuqiang Li, K. Livak, D. Neuberg, 2023, Blood.

Tutorial: integrative computational analysis of bulk RNA-sequencing data to characterize tumor immunity using RIMA

Henry W. Long, X. Liu, C. Tokheim, 2023, Nature Protocols.

Comprehensive characterizations of immune receptor repertoire in tumors and cancer immunotherapy studies.

K. Livak, Heng Li, Bo Li, 2022, Cancer immunology research.

Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities

Sudheshna Bodapati, Jennifer Altreuter, Cheryl J Wong, 2023, Cell genomics.

Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma

E. Cerami, D. D. Del Valle, S. Kim-Schulze, 2024, Cancer research communications.

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.

S. Harmon, B. Turkbey, H. Maecker, 2023, Cancer cell.